One Gene, Two States: Truncating Loss Versus Retained Full-Length p53 in Solid and Hematologic Cancers

TP53 mutations create two functionally opposite states—loss of the protein or retention of a full-length mutant protein—yet are usually reported as one entity. How the two states are distributed between solid tumors and hematologic malignancies has not been quantified. In one pipeline integrating ≈64,000 samples (29 solid-tumor types, 19 hematologic cohorts and a 42,714-sample post-therapy clonal-hematopoiesis cohort), we asked which state is selected where, what it does, and what it offers. Truncating mutations accounted for 34.2% of solid but 24.4% of hematologic alterations (χ2 = 33.7, p = 2.3 × 10−7; reproduced in the NCI TP53 and COSMIC databases). Where copy number resolves allelic state, 60.6% of missense-mutant solid tumors had lost the wild-type allele (19.5% biallelic inactivation). Blood retained full-length missense protein instead, and in MDS, outcome tracked the retained-allele dose (hazard ratio 1.78, p = 1.0 × 10−4); in solid tumors, no survival difference was detected by allelic state. The endogenous CpG baseline is equivalent (20.7% versus 21.2%), while solid spectra carry exogenous exposure fingerprints. Only the retained state presents a target, so allele-specific reactivation is the rational corollary where retention prevails—a hypothesis, as retention in blood is inferred from mutation class.